FORTE: Impact of imaging FDG-PET/CT minimal residual disease assessment on multiple myeloma patients

ASCENT: A phase II trial of induction, consolidation and maintenance in subjects with high risk smouldering MM

Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment

Treating acute leukaemias of ambiguous lineage

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma

Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin lymphoma real world evidence data

Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-year results

FORTE trial: Impact of minimal residual disease on multiple myeloma patients

Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Treated on the Interfant-06 protocol

PARP inhibitors in prostate cancer: A promise delivered

Clinical genomic testing in prostate cancer

PARP inhibitors for prostate cancer - Nurse's view